Oncology Venture participates at Biotech Showcase in the US

Hoersholm, Denmark; December 22nd, 2015 – Oncology Venture Sweden AB (OV:ST) announces that the Company will be present and have 1:1 meetings with potential new investors as well as Big Pharma and Biotech companies at the Biotech Showcase in San Francisco from the 11-13 February 2016. The conference is held in connection with the JPMorgan Health Conference and decision makers from the international pharma and biotech industry will be present in San Francisco during that period.

For more information on Biotech Showcase 2016, please visit:

http://www.ebdgroup.com/bts/index.php

For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.